The heart matters when the liver shatters!
Cirrhotic cardiomyopathy: frequency, comparison, and correlation with severity of disease

Iftikhar Haider Naqvi, Khalid Mahmood, Muhammad Naeem, Aneel Sham Vashwani, Syed Ziaullah
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan

Gastroenterology Rev 2016; 11 (4): 247–256
DOI: 10.5114/pg.2016.57962

Key words: cardiomyopathy, liver cirrhosis, stress echocardiography, ascites, paracentesis.

Address for correspondence: Dr. Iftikhar Haider Naqvi, Department of Medicine, Dow University of Health Sciences, Mission Rd, Karachi 74200, Pakistan, e-mail: drihnaqvi@gmail.com

Abstract

Introduction: Cirrhotic cardiomyopathy is a visor complication among patients with cirrhosis of the liver, manifesting during stress, exertion, transjugular intrahepatic portosystemic shunt (TIPS), or liver transplantation. Cirrhotic cardiomyopathy is reported to be most common cause of post transplant mortality after rejection of 7% to 21%.

Aim: To determine the frequency of cirrhotic cardiomyopathy and was further designed to compare parameters of cardiac dysfunction in patients with or without cirrhotic cardiomyopathy.

Material and methods: All confirmed cases of cirrhosis with various aetiologies were enrolled. Resting ejection fraction (EF) was determined in all patients. Patients were grouped with resting EF < 55% (suspected cardiomyopathy) or > 55% (without cardiomyopathy). Stress echocardiography with dobutamine infusion in both groups yielded an increase of less than 10% in left ventricular (LV) EF at peak dobutamine infusion confirming systolic dysfunction. The diastolic dysfunction (E/A ratio), electrocardiographic parameter (prolong QT interval), and cardiac biomarker (NT-proBNP) were also determined in both the groups to confirm cirrhotic cardiomyopathy.

Results: Among 89 patients with cirrhosis, 35 (39.32%) had cirrhotic cardiomyopathy. All components of cirrhotic cardiomyopathy, like systolic dysfunction, diastolic dysfunction, prolong QT interval, and cardiac biomarker (NT-proBNP) were found to be statistically significant \((p = 0.001)\) when compared with patients without cardiomyopathy. Cirrhotic cardiomyopathy parameters were positively correlated with advancing liver disease.

Conclusions: Cirrhotic cardiomyopathy is a frequent but unmasked complication in cirrhosis of the liver. All components of cardiac dysfunction, such as systolic, diastolic, and electrocardiographic changes, are present in patients with cirrhotic cardiomyopathy. Cirrhotic cardiomyopathy is positively correlated to severity of liver disease.

Introduction

Hyperdynamic circulatory response in cirrhosis of the liver was described more than half a century ago, where impaired thiamine metabolism or endogenous vasodilators were implicated for increased cardiac output [1]. Earlier studies revealed circulatory and cardiac dysfunction among cirrhotics predominantly due to peripheral vasodilatation [2]. There is now considerable substantiation that hyperdynamic syndrome in cirrhosis of the liver is because of deranged liver function and portal hypertension [3, 4]. In cirrhosis of the liver, circulating blood volume is redistributed to splanchnic circulation, resulting in significant hypovolaemia, which consequently activates the sympathetic nervous system [5]. This additionally aggravates the hyperdynamic circulation and thus cardiac strain.

The term “cirrhotic cardiomyopathy” emerged on the basis of experimental and clinical studies denoting impaired myocardial contractility as well as electrophysiological abnormalities in cirrhosis [6]. Cirrhotic cardiomyopathy is defined as chronic cardiac dysfunction, characterised by blunted contractile responsiveness to stress, altered diastolic relaxation, with electrophysiological abnormalities (QT interval prolongation) in the absence of any other cardiac disease [7].
The exact prevalence of cirrhotic cardiomyopathy is unknown; recent studies have shown its frequency to be 3% to 23.4% [8, 9]. Therefore, the natural history of the disease is not well known. The condition remains asymptomatic and well tolerated for months to years. The response to treatment and prognosis of cirrhotic cardiomyopathy is vague. Cirrhotic cardiomyopathy is unmasked (ventricular insufficiency) when complications like upper GI haemorrhage and SBP cause haemodynamic changes in peripheral and splanchic circulation. Cirrhotic cardiomyopathy has been reportedly the most common cause of post transplant mortality after rejection with 7% to 21% mortality [10].

The diastolic dysfunction in cirrhotic cardiomyopathy can be assessed with Doppler echocardiography (decreased E/A ratio, delayed relaxation time) [11]. Masked cardiac systolic dysfunction in cirrhotics can be assessed by dobutamine stress echocardiography [11]. Electrophysiological abnormalities (prolongation of the QT interval) and serum cardiac biomarkers like proBNP are important diagnostic parameters for cirrhotic cardiomyopathy [12, 13].

Pakistan has a high burden of liver cirrhosis with advanced disease Child Turecott Pugh (CTP) stage B and C [14, 15]. Patients with cirrhosis of the liver have a higher rate of complications and an overall increased mortality. Upper gastrointestinal haemorrhage, spontaneous bacterial infection, and repeated paracentesis in cases of refractory ascites are important inciting events in these patients for unmasking cardiac dysfunction (cirrhotic cardiomyopathy). The published data on cirrhotic cardiomyopathy in Pakistan is mostly based on either the systolic dysfunction or ECG parameters in cirrhotic patients [16, 17]. This particular study accentuate on current consensus defining criteria of cirrhotic cardiomyopathy as proposed by world congress of Gastroenterology (Montreal proposal) [13] where systolic, diastolic, electrocardiographic and serum cardiac biomarker all were determined.

**Aim**

The objectives of the study were: 1) to determine the frequency of cirrhotic cardiomyopathy and to compare parameters of cardiac dysfunction in patients with and without cirrhotic cardiomyopathy; 2) relate the severity of liver cirrhosis with parameters of cirrhotic cardiomyopathy.

**Material and methods**

Institutional Ethics Committee approval was sought before commencing the study. It was a hospital based, prospective, analytical study performed on patients with the diagnosis of cirrhosis of the liver in a medical unit of the civil hospital in Karachi from July 2014 to September 2014. All confirmed cases of cirrhosis with age > 18 years with various aetiologies were included except alcoholic cirrhosis and haemochromatosis because these two conditions can have dilated cardiomyopathy as a consistent feature. Patients with known hypertension, cardiac, endocrine, and renal disease were excluded. Patients with recent haemorrhage within 1–2 months, haemoglobin < 7 g/dl, serum creatinine > 1.5 mg/dl, and using drugs that might prolong QT interval were also excluded.

**Study protocol**

**Cirrhosis of the liver**

Cirrhosis of the liver was diagnosed on clinical, biochemical, radiological (trans-abdominal ultrasound or computerised tomography had to demonstrate a small shrunken liver with or without splenomegaly and infra-abdominal varices), and histopathological grounds, wherever required [15]. Severity of cirrhosis was determined in accordance to CTP stages CTP-A, CTP-B, and CTP-C.

**Cirrhotic cardiomyopathy**

As there are no definitive criteria for diagnosis of cirrhotic cardiomyopathy it was diagnosed in accordance with the Montreal proposal at the World Congress of Gastroenterology consensus definition [13]. According to this study, cirrhotic cardiomyopathy was confirmed on the following:

**Systolic dysfunction**

Resting ejection fraction (EF < 55%), blunted increase in cardiac output with dobutamine stress echocardiography, where blunted response is defined as < 10% increase in resting EF [18].

**Diastolic dysfunction**

Diastolic dysfunction is labelled through echocardiographic estimation of ventricular relaxation: atrial contraction (E/A ratio), diastolic dysfunction is graded according to E/A ratio (E/A ratio < 1.0, may be reversed to > 2 in case of severe diastolic dysfunction) [19]. Deceleration time (DT) and intra ventricular relaxation time (IVRT) as other parameters for diastolic dysfunction were also determined. Diastolic dysfunction was labelled when DT > 200 ms and IVRT > 80 ms [13].

**Supportive criteria**

Cardiac biomarker, NT pro basic natriuretic peptide (NT-proBNP level > 144 pg/ml) and corrected prolonged QT interval (QTc > 440 ms) on ECG were two supportive criteria used in this study to confirm cirrhotic cardiomyopathy.
The heart matters when the liver shatters! Cirrhotic cardiomyopathy: frequency, comparison, and correlation with severity of disease

Gastroenterology Review 2016; 11 (4)

**N Terminal prohormone brain natriuretic hormone (NT-proBNP)**

The increased pro-BNP level, determined via Elecsys NT-proBNP assay (Roche diagnostics, Mannheim, Germany). The cut-off level for cirrhotic cardiomyopathy was > 144 pg/ml [20].

**Corrected QT interval (QTc interval)**

QTc interval was calculated through online QTc calculator [21] where Bazetts formula QTc = QT/√RR was used for correction. QTc interval ≥ 440 ms is considered abnormal QTc.

Resting EF was determined in all cirrhotic patients. Patients with resting EF < 55% were suspected of having cirrhotic cardiomyopathy whereas patients with resting EF > 55% were considered otherwise. Stress echocardiography was carried out in both groups, and rise in resting EF of not more than 10% confirmed cardiomypathy. The other group, with resting EF rise > 10% after stress echocardiography, was labelled as without cirrhotic cardiomyopathy. The diastolic dysfunctions (E/A ratio), electrocardiographic parameter (prolong QT interval), and cardiac biomarker (NT-proBNP) were also determined in both the groups. These parameters further confirm cirrhotic cardiomyopathy.

**Resting echocardiography**

Three-dimensional colour Doppler echocardiography was done in all patients with cirrhosis in accordance with the protocol of the American Society of Echocardiography [22]. The resting ejection fraction and E/A ratio were estimated. Diastolic dysfunction was graded in accordance with the E/A ratio.

**Stress echocardiography**

All patients underwent stress echocardiogram with graded dobutamine infusion starting at 5 μg/kg/min increasing at 3-minute intervals to a maximum of 40 μg/kg/min, in accordance with guidelines for stress echocardiography given by the American Society of Echocardiography [23], and ejection fraction was estimated at peak infusion. The blunted systolic response was labelled if the increase in resting EF was < 10%.

**Statistical analysis**

The data of the study were entered into Statistical Packages for the Social Sciences (SPSS) version 15.0 (SPSS Inc, Chicago, IL, USA) for statistical analysis. For continuous variables the means and standard deviations were calculated, while percentages and proportions were used for discrete variables. For comparing parametric and non-parametric data of patients the Student t test and χ² test were applied where p-values < 0.05 were considered as statistically significant.

**Results**

Out of total 89 patients of cirrhosis 35 (39.32%) patients had cirrhotic cardiomyopathy while 59.55% had no evidence of cardiomypathy. Overall mean age of patients with cirrhosis was 51.49 ±12.42 years. Patients with cirrhotic cardiomyopathy had a mean age of 53.71 ±8.95 years while patients without cirrhotic cardiomyopathy had a mean age of 49.57 ±14.09 years. Most of the patients with cirrhosis were male 50 (56.17%) while 39 (43.82%) were females. The further gender distribution in both groups with and without cirrhotic cardiomyopathy is given in Table I.

The most common cause of cirrhosis was chronic hepatitis C in 53 (59.55%) patients and hepatitis B in 31 (34.83%) patients, followed by autoimmune in three patients (3.37%), and Wilson disease in 2 (2.24%) patients. The distribution of causes of cirrhosis in both the groups with and without cardiomypathy is given in Table I. Most of the patients in this study had advanced liver diseases, with 43 (48.31%) patients in CTP-B and 29 (32.58%) patients in CTP-C category. The severity of liver disease CTP stages in both cardiomyopathy and without cardiomypathy group are also highlighted in Table I.

**Systolic dysfunction**

Out of 89 patients of liver cirrhosis 35 (39.32%) had resting EF (%) < 55 while in 54 (59.55%) it was > 55. The mean resting EF of each group according to CTP stage of liver disease is highlighted in Table II. Resting EF when compared in each group remained statistically insignificant. Stress EF was determined in both groups in accordance with CTP staging of cirrhosis. In patients with suspected cardiomyopathy resting EF < 55 was increased after dobutamine infusion (stress EF) to 57.95 ±0.31% in CTP-A, 57.04 ±0.40% in CTP-B, and 55.78 ±0.56% in CTP-C. The stress EF failed to rise > 10% from their resting value in this group, which confirms systolic dysfunction. In patients without suspected cardiomyopathy, where resting EF was > 55% after dobutamine infusion, EF was increased to 62.46 ±0.51% in CTP-A, 60.55 ±0.49% in CTP-B, and 57.17 ±0.77% in CTP-C. The stress EF increased to > 10% from their resting value ruled out underlying systolic dysfunction in these patients. Stress EF values in the cirrhotic cardiomyopathy group, when compared with the non-cirrhotic group in accordance with severity of liver diseases, have a statistically significant p-value of 0.001, as shown in Table II.
Diastolic dysfunction

The diastolic dysfunction E/A ratios were determined on echocardiography in patients with and without cardiomyopathy. In patients with cardiomyopathy, diastolic dysfunction E/A ratio in accordance to severity of liver disease was 0.915 ±0.02 in CTP-A, 0.87 ±0.03 in CTP-B, and 1.775 ±0.25 in CTP-C. Diastolic dysfunction E/A ratio increases with severity of liver disease. In patients without cardiomyopathy the E/A ratios were 1.24 ±0.01 in CTP-A, 1.29 ±0.01 in CTP-B, and 1.32 ±0.21 in CTP-C. Diastolic dysfunction was compared in both groups in accordance with severity of liver diseases and had a statistically significant p-value of 0.001, as shown in Table II. In patients with cardiomyopathy, diastolic dysfunction deceleration times (DT) in accordance with severity of liver disease were 226.84 ±11.72 ms CTP-A, 76.755 ±14.95 ms in CTP-B, and 70.23 ±4.54 ms in CTP-C. Diastolic dysfunction DT, compared in both groups in accordance with severity of liver diseases, has a statistically significant p-value, as shown in Table II.

Electrocardiographic changes

The corrected QT interval (QTc) was determined through ECG in patients with cardiomyopathy and without cardiomyopathy. In patients with cardiomyopathy, corrected QT intervals in accordance with severity of liver disease were 482.17 ±1.639 ms in CTP-A, 530.09 ±1.92 ms in CTP-B, and 590.75 ±1.86 ms in CTP-C. The prolongation of QT interval increases with severity of liver disease. In patients without cardiomyopathy corrected QT intervals were 400.23 ±0.66 ms in CTP-A, 416.11 ±0.50 ms in CTP-B, and 435.66 ±1.07 ms in CTP-C. QTc interval was compared in both groups in accordance with severity of liver diseases and was shown to have a statistically significant p-value of 0.001, as shown in Table II.

NT pro brain natriuretic peptide (NT-proBNP)

The cardiac biomarker NT-proBNP level was determined in patients with cardiomyopathy and without cardiomyopathy. In patients with cardiomyopathy, NT-proBNP level in accordance with severity of liver disease were 85.85 ±13.17 ms in CTP-A, 85.57 ±3.80 ms in CTP-B, and 76.25 ±10.01 ms in CTP-C. The determination of NT-proBNP level increases with severity of liver disease. In patients without cardiomyopathy NT-proBNP level was 85.06 ±13.01 ms in CTP-A, 85.57 ±3.80 ms in CTP-B, and 76.25 ±10.01 ms in CTP-C. NT-proBNP level, compared in both groups in accordance with severity of liver diseases, was shown to have a statistically significant p-value of 0.001, as shown in Table II.
ease was 151.5 ±4.50 pg/ml in CTP-A, 1781.0 ±4.30 pg/ml in CTP-B, and 188.36 ±6.15 pg/ml in CTP-C. The NT-proBNP level increases with severity of liver disease. In patients without cardiomyopathy NT-proBNP level was 103.23 ±3.65 pg/ml in CTP-A, 118.27 ±2.63 pg/ml in CTP-B, and 136.08 ±3.14 pg/ml in CTP-C. NT-proBNP levels were compared in both groups in accordance with severity of liver diseases and were shown to have a statistically significant p-value of 0.001, as shown in Table II.

Table II. Comparison of cardiac dysfunctions in patients with and without cirrhotic cardiomyopathy

| Parameters of cirrhotic cardiomyopathy | Patients with resting EF < 55% (suspected cirrhotic cardiomyopathy) n = 35 | Patients with resting EF > 55% (suspected without cirrhotic cardiomyopathy) n = 54 | P-value |
|----------------------------------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------|---------|
| **Systolic:**                           |                                                                          |                                                                             |         |
| Resting EF %:                           |                                                                          |                                                                             |         |
| CTP-A                                  | 4 (11.42%) 54.55 ±0.58                                                   | 13 (24.07%) 55.33 ±0.88                                                    | 0.65    |
| CTP-B                                  | 11 (31.42%) 53.72 ±0.26                                                   | 18 (33.33%) 55.93 ±0.44                                                    | 0.16    |
| CTP-C                                  | 20 (57.14%) 53.33 ±0.67                                                   | 23 (49.59%) 56.31 ±0.36                                                    | 0.91    |
| Stress EF (> 10% increase after dobutamine infusion): |                                                                          |                                                                             |         |
| CTP-A                                  | 4 (11.42%) 57.95 ±0.31                                                   | 13 (24.07%) 62.46 ±0.51                                                    | < 0.001 |
| CTP-B                                  | 11 (31.42%) 57.04 ±0.40                                                   | 18 (33.33%) 60.55 ±0.49                                                    | < 0.001 |
| CTP-C                                  | 20 (57.14%) 55.78 ±0.56                                                   | 23 (49.59%) 57.17 ±0.77                                                    | < 0.001 |
| **Diastolic:**                          |                                                                          |                                                                             |         |
| E/A ratio:                             |                                                                          |                                                                             |         |
| CTP-A                                  | 4 (11.42%) 0.91 ±0.02                                                    | 13 (24.07%) 1.24 ±0.01                                                    | < 0.001 |
| CTP-B                                  | 11 (31.42%) 0.87 ±0.03                                                   | 18 (33.33%) 1.29 ±0.01                                                    | < 0.001 |
| CTP-C                                  | 20 (57.14%) 1.775 ±0.25                                                   | 23 (49.59%) 1.32 ±0.21                                                    | < 0.001 |
| Deceleration time:                     |                                                                          |                                                                             |         |
| CTP-A                                  | 4 (11.42%) 226.84 ±11.72                                                  | 13 (24.07%) 169.21 ±26.27                                                  | < 0.001 |
| CTP-B                                  | 11 (31.42%) 76.755 ±14.95                                                  | 18 (33.33%) 85.57 ±3.80                                                    | 0.023   |
| CTP-C                                  | 20 (57.14%) 70.23 ±4.54                                                   | 23 (49.59%) 135.80 ±17.94                                                  | < 0.001 |
| Isovolumetric relaxation time (IVNRT): |                                                                          |                                                                             |         |
| CTP-A                                  | 4 (11.42%) 114.87 ±9.59                                                   | 13 (24.07%) 85.85 ±13.17                                                   | 0.001   |
| CTP-B                                  | 11 (31.42%) 90.99 ±3.68                                                   | 18 (33.33%) 85.57 ±3.80                                                    | < 0.001 |
| CTP-C                                  | 20 (57.14%) 84.75 ±5.63                                                   | 23 (49.59%) 76.25 ±10.01                                                   | 0.003   |
| ECG changes QT, interval:              |                                                                          |                                                                             |         |
| CTP-A                                  | 4 (11.42%) 482.17 ±16.39                                                  | 13 (24.07%) 400.23 ±0.66                                                   | < 0.001 |
| CTP-B                                  | 11 (31.42%) 530.09 ±1.92                                                  | 18 (33.33%) 416.11 ±0.50                                                   | < 0.001 |
| CTP-C                                  | 20 (57.14%) 590.75 ±1.86                                                  | 23 (49.59%) 435.66 ±1.07                                                   | < 0.001 |
| NT-proBNP level [pg/ml]:              |                                                                          |                                                                             |         |
| CTP-A                                  | 4 (11.42%) 151.5 ±4.50                                                   | 13 (24.07%) 103.23 ±3.65                                                   | < 0.001 |
| CTP-B                                  | 11 (31.42%) 1781.0 ±4.30                                                  | 18 (33.33%) 118.27 ±2.63                                                   | < 0.001 |
| CTP-C                                  | 20 (57.14%) 188.36 ±6.15                                                  | 23 (49.59%) 136.08 ±3.14                                                   | < 0.001 |
Association between various parameters of cardiomyopathy with severity of liver disease

The association between various parameters of cardiomyopathy with severity of liver disease was determined in all patients. All parameters, including resting EF, stress EF, increase in > 10% EF after pharmacologic stimuli, and cardiac biomarker (NT-proBNP), showed significant association with severity of liver disease except corrected QT interval, as shown in Table III.

Comparison of cardiac dysfunction

Various components of cardiac dysfunction in cirrhotic cardiomyopathy were compared with patients without cardiomyopathy. Resting EF in the group with cardiomyopathy and without cardiomyopathy remained statistically insignificant (p = 0.255), as shown in Table IV. Increase in resting EF > 10% after stress was found to be statistically significant in patients with cardiomyopathy when compared with patients without cardiomyopathy (p ≤ 0.001), as depicted in Table IV. Diastolic dysfunction E/A ratio was found to be statistically significant in the cardiomyopathy group when compared to patients in the group without cardiomyopathy (p ≤ 0.001), as illustrated in Table IV. Elevation of cardiac biomarker NT-proBNP was found to be statistically significant in the cardiomyopathy group when compared to patients in the group without cardiomyopathy (p ≤ 0.001), as shown in Table IV.

Discussion

Most patients with cirrhosis are complicated by ascites, volume overload, and signs of hyperdynamic circulation. They have normal resting echocardiographic parameters, but abnormal cardiac responses during stress, exertion, TIPS, or liver transplantation, consistent with cirrhotic cardiomyopathy [24]. In this study the frequency of cirrhotic cardiomyopathy was 39.32%. An earlier local study [25] showed a slightly higher frequency (44%) of cirrhotic cardiomyopathy in comparison to our study. The higher frequency of cirrhotic cardiomyopathy in the above-mentioned study is possibly due to its small sample size. In an above-mentioned study cirrhotic cardiomyopathy was not confirmed on stress echocardiography. Recent studies [8, 9] showed the frequency of cirrhotic cardiomyopathy ranging from 3–23%, which is slightly lower than seen in this study.

The most common cause of cirrhosis found was chronic hepatitis C and hepatitis B. The frequency of chronic viral hepatitis correlates to their prevalence in Pakistan and Asia, where 60–70% of cirrhotics are...
The high prevalence of chronic hepatitis C is further endorsed by recent studies that have shown that 50% cases of hepatocellular carcinoma in Pakistan are anti-HCV positive [30]. Pakistan is in the intermediate HBV prevalence area with a carrier rate of 3–4% [31], also emphasising that HBV is an important cause of cirrhosis of the liver [32]. The majority of the patients in this study had advanced cirrhosis of the liver: 43 (48.31%) patients in CTP-B and 29 (32.58%) patients in CTP-C the category, which is similar to former studies [32–34]. An earlier study [33] contrasted to our study and showed less advanced chronic liver disease (CTP-C – 15% and CTP-B – 35%). More severe disease in this study as compared to western studies is probably due to an ineffective health care system, lack of education, poverty, and false beliefs about the disease.

Systolic dysfunction was discovered to be an important component of the cirrhotic cardiomyopathy of this study. Resting EF < 55% was present in 39.32% of patients, while 59.55% patients had EF > 55%. On stress echocardiography patients with < 55% EF (suspected cardiomyopathy) failed to show an increase > 10% in resting EF, which confirms systolic dysfunction. Patients with resting EF > 55% showed an increase of > 10% in their resting EF on stress echocardiography, which ruled out systolic dysfunction in this group. An earlier local study of cirrhics showed systolic dysfunction of 33.8% in their patients, although systolic dysfunction was not confirmed on stress echocardiography, but it was assessed just on the basis of resting EF (< 55% or > 55%) [25].

A recent study on Korean patients with cirrhosis of the liver showed 25.5% systolic dysfunction on stress echocardiography [35]. The above-mentioned study used the same criteria for systolic dysfunction on stress echocardiography as in this study. Systolic dysfunction tends to increase with severity of liver disease (in accordance to Child-Pugh staging) in this study. An earlier study also demonstrated worsening of systolic functions with increasing severity of liver disease [25]. Recent clinical and experimental studies are also congruent with this study and show the correlation between the extent of cirrhotic cardiomyopathy and the severity of liver disease [36, 37].

Diastolic dysfunction is considered to be present in almost all patients with cirrhotic cardiomyopathy; it may be diagnosed with simple echocardiographic diastolic dysfunction indices such as the E/A ratio even

---

**Table IV. Comparison of cardiac parameters in patients with and without cardiomyopathy**

| Parameters                      | Cirrhotic cardiomyopathy | \(\chi^2/t\)-test statistic | \(P\)-value |
|---------------------------------|--------------------------|-----------------------------|-------------|
|                                 | Yes                      | No                          |             |
|                                 | Frequency | Percentage | Frequency | Percentage | \(\chi^2/t\) |               |
| Child-Pugh staging:            |           |            |           |            |               |               |
| Child Pugh A                    | 4         | 23.5       | 13        | 76.5       | 2.732        | 0.255         |
| Child Pugh B                    | 11        | 37.9       | 18        | 62.1       |               |               |
| Child Pugh C                    | 20        | 46.5       | 23        | 53.5       |               |               |
| Increase in 10% EF after stress echocardiography: | | | | | | |
| Yes                             | 0         | 0          | 32        | 100.0      | 32.38        | < 0.001       |
| No                              | 35        | 61.4       | 22        | 38.6       |               |               |
| E/A ratio:                      |            |            |           |            |               |               |
| < 1                             | 15        | 93.8       | 1         | 6.2        | 24.21        | < 0.001       |
| > 1                             | 20        | 27.4       | 53        | 72.6       |               |               |
| Corrected QT interval [ms]:     |            |            |           |            |               |               |
| < 440                           | 1         | 2.1        | 47        | 97.9       | 60.56        | < 0.001       |
| > 440                           | 34        | 82.9       | 7         | 17.1       |               |               |
| Ejection fraction at rest (%)   | 53.59 ±0.68| 53.76 ±0.6871 | –1.161 | 0.249 | | |
| NT-proBNP                       | 176.03 ±15.82| 122.24 ±13.65 | 17.04 | < 0.001 | | |
at rest. The E/A ratio has been proposed recently as a predictive marker for survival after TIPS [38, 39]. In this study diastolic dysfunction (based on E/A ratio) was found in patients with cirrhotic cardiomyopathy and remains statistically significant when compared with patients without cirrhotic cardiomyopathy ($p < 0.001$). Diastolic dysfunction increases with severity of liver disease in this study. A previous local study also showed diastolic dysfunction in patients with cirrhotic cardiomyopathy and gave a positive correlation between the cirrhotic cardiomyopathy with severity of liver disease [25]. Valeriano et al. also showed diastolic dysfunction within patients having cirrhotic cardiomyopathy when compared with healthy controls [40].

The limitation of the above study is its comparison with healthy controls not within the subgroups of cirrhosis itself. Although some diastolic alterations may precede systolic disturbances, both types of dysfunction may develop simultaneously in cirrhatic patients. Diastolic dysfunction has also been reported in non-cirrhotic portal hypertension and in patients with ascites but without cardiac hypertrophy [40]. Diastolic dysfunctions may improve after paracentesis and albumin infusion [41]. In this study other parameters of diastolic dysfunction, like DT and IVRT, were also determined and were found to be impaired in patients with cirrhotic cardiomyopathy. Earlier studies have also shown impaired DT and IVRT in patients with cirrhotic cardiomyopathy, which is congruent with this study [42, 43].

Independent to the cause of cirrhosis, multiple electrical abnormalities (QT-interval abnormalities, electrical and mechanical dyssynchrony, and chronotropic incompetence) have been recognised, which is related to autonomic dysfunction. Patients with cirrhosis have prolongation of the QT interval ($> 0.44$ s) even with mild increments in portal pressure [44]. It has been suggested that both delayed repolarisation of cardiomyocytes ($K^\text{-}channel abnormalities$) and sympathoadrenergic hyperactivity may contribute to QT-interval prolongation [45]. QT interval was prolonged in this study in patients with cirrhotic cardiomyopathy. Prolongation of QT interval was found to be statistically significant ($p = 0.001$) when compared to patients without cardiomyopathy.

An earlier local study [25] also showed prolongation of QT interval in patients with cirrhotic cardiomyopathy. In this study prolongation of QT interval was correlated with severity of liver disease as maximum prolongation was noted in CTP C. Genovesi et al. [46] in their study also found prolongation of QT interval in cirrhosis of the liver and having positive correlation with severity of cirrhosis, as in this study. However, the above study also showed a significant relationship between prolonged QT interval and hepatic venous pressure gradient. Previous studies were also in agreement with this study because they have shown prolongation of QT interval and its correlation with severity of liver disease [47–49].

Recently, considerable attention has been paid to the cardiac biomarkers: BNP and its pro-hormone NT-proBNP, which are released by heart ventricles in response to massive stretching of muscle cells, or to mild cardiac damage [50, 51]. Furthermore, recent studies showed that elevated serum levels of NT-proBNP are found in patients with cirrhosis of viral aetiology [52, 53]. The relation of NT-proBNP with the severity of liver disease and cardiac dysfunction made it a useful marker for cirrhotic cardiomyopathy [54].

In this study NT-proBNP level was elevated in patients with cardiomyopathy, and, when compared with patients without cirrhotic cardiomyopathy, was found to be statistically significant ($p = 0.001$). NT-proBNP level had a positive correlation with severity of liver disease. An earlier local study also showed increased levels of NT-proBNP in cirrhotic cardiomyopathy with positive correlation with severity of liver disease [25]. Cavaşi et al. have also shown the positive correlation of NT-proBNP with advancing stage of cirrhosis, which is congruent to this study [55]. A study by Radvan et al. reported a significant correlation between serum BNP levels and MELD scores [56]. Kim et al. in their study have shown that elevated BNP in patients with end-stage liver disease may reflect increased pulmonary arterial pressure, and predicts post-transplant mortality [57]. In conclusion, serum BNP level is correlated significantly with the stage of cirrhosis, hepatocellular failure, and portal hypertension. Therefore, serum BNP level can be used as a valuable parameter in predicting the prognosis of, and monitoring the response to, therapy in cirrhotic cardiomyopathy.

**Conclusions**

Cirrhotic cardiomyopathy is a frequent but hidden complication in patients with cirrhosis of the liver. All components of cardiac dysfunction like systolic, diastolic, and electrocardiographic changes are present in patients with cirrhotic cardiomyopathy. Cirrhotic cardiomyopathy has a positive correlation with severity of liver disease.

**Conflict of interest**

The authors declare no conflict of interest.

**References**

1. Shorr E, Zweifach BW, Furchgott RF, Baez S. Hepatorenal factors in circulatory homeostasis. IV. Tissue origins of the vaso-tropic principles, VEM and VDM, which appear during evolution of hemorrhagic and tourniquet shock. Circulation 1951; 3: 42-79.
2. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest 1953; 32: 1025-33.
3. Møller S, Henrikse JS. The systemic circulation in cirrhosis. In: Ascites and renal dysfunction in liver disease. Gines P, Arroyo V, Rodes J, Schrier RW (eds). Blackwell, Malden 2005; 139-55.
4. Wakiri Y, Grossmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006; 43: S121-31.
5. Møller S, Iversen JS, Henrikse JH, Bendtsen F. Reduced baroreflex sensitivity in alcoholic cirrhosis: relations to hemodynamics and humoral systems. Am J Physiol Heart Circ Physiol 2007; 292: H2966-72.
6. Alqahtani SA, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Semin Liver Dis 2008; 28: 59-69.
7. Møller S, Henrikse JH. Cardiovascular complications of cirrhosis. Gut 2008; 57: 268-78.
8. Enache I, Oswald-Mammosser M, Woehl-Jaegle ML, et al. Cirrhotic cardiomyopathy and hepatopulmonary syndrome: prevalence and progression in a series of patients. Respir Med 2013; 107: 1030-6.
9. Prevalence of diastolic dysfunction and other supportive criteria of cirrhotic cardiomyopathy. Available at http://www.kenes.com/ easl2010/posts/Abstract78.htm. Accessed on April 2012.
10. Finucci G, Desideri A, Sacardoti D, et al. Left ventricular diastolic function in liver cirrhosis. Scand J Gastroenterol 1996; 31: 279-84.
11. Kim Y, Baik SK, Suk KT, et al. Dobutamine stress echocardiography: a new screening method for evaluating cirrhotic cardiomyopathy in liver cirrhosis. Hepatology 2008; 48: 1064F.
12. Potter LR, Yoder AR, Flora DR, et al. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 2009; 191: 341-66.
13. Møller S, Henrikse JH. Cirrhotic cardiomyopathy. J Hepatol 2010; 53: 179-90.
14. Butt S, Ahmed P, Liaquat P, Ahmed H. A study of malnutrition among liver disease patients. Pak J Nutr 2009; 8: 1465-71.
15. Naqvi IH, Mahmood K, Saleekeen S, Akhter ST. Determining the frequency and severity of malnutrition and correlating it with the severity of liver cirrhosis. Turk J Gastroenterol 2013; 24: 415-22.
16. Abbasi SM, Aamir Y, Gul S, et al. Can heart rate and QTc duration be used as a marker of cirrhotic cardiomyopathy? A case control study. J Postgrad Med Inst 2012; 26: 363-8.
17. Ahmed Ul, Shaukat A, Shaukat A, Aamir H. Prolongation of QTc duration and increased heart rate in patients with cirrhosis of liver. APMC 2012; 6: 28-31.
18. Coletta C, Galati A, Ricci R, et al. Prognostic value of left ventricular volume response during dobutamine stress echocardiography. Eur Heart J 1997; 18: 1599-605.
19. Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol 2009; 104: 2458-67.
20. Woo JJ, Koh YK, Kim HI, et al. N-terminal pro B-type natriuretic peptide and the evaluation of cardiac dysfunction and severity of disease in cirrhotic patients. Med J 2008; 49: 625-63.
21. QT Interval Correction Calculator – Medscape Reference. Cited on 14th January 2014 available at: http://reference.medscape.com/calculator/qt-interval-correction-ekg
22. Lang RM, Badano LP, Tsang W, et al. EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography. J Am Soc Echocardiogr 2012; 25: 3-42.
23. Pellikka PA, Nagueh SF, Elhendy AA, et al. American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. J Am Soc Echocardiogr 2007; 20: 1021-34.
24. Ripoll C, Catalina MV, Yotti R, et al. Cardiac dysfunction during liver transplantation: incidence and preoperative predictors. Transplantation 2008; 85: 1766-72.
25. Shaikh S, Abro M, Qazi I, Yousafani A. Frequency of cirrhotic cardiomyopathy in patients with cirrhosis of liver: a tertiary care hospital experience. Pak J Med Sci 2011; 27: 744-8.
26. Khan AA, Rehman KU, Haidar Z, Shafqat F. Sero-markers of hepatitis B and C in patients with cirrhosis. J Coll Phys Surg Pak 2002; 12: 105-7.
27. Umar M, Khaar HB, Anwar F, Zahid M. The management of acute variceal bleeding by octreotide. J Rawal Med Coll 2000; 4: 14-6.
28. Hamid S, Tabbasum S, Jafri W. Hepatitis C has replaced hepatitis B as the major cause of chronic liver disease in Pakistan. Hepatology 1999; 30: 212-27.
29. Chohan AR, Umar M, Khaar B, et al. Demographic features of hepatocellular carcinoma. A study of 30 cases. J Rawal Med Coll 2001; 5: 83-3.
30. Umar M, Bushra HT, Younis N, Bashir N. Clinical spectrum of chronic liver disease due to HBV, HCV and dual infection – a comparative study. Pak J Gastroenterol 1999; 13: 1-3.
31. Andre F. Hepatitis B epidemiology in Asia: the Middle East and Africa. Vaccine 2000; 18 (Suppl. 1): S20-2.
32. Butt S, Ahmed P, Liaquat P, Ahmed H. A study of malnutrition among liver disease patients. Pak J Nutr 2009; 8: 1465-71.
33. Tal MI, Goh KJ, Mohd-Taib SH, et al. Anthropometric, biochemical and clinical assessment of malnutrition in Malaysian patients with advanced cirrhosis. Nutr J 2010; 9: 27.
34. Attia KA, Ackoundou-N’guessan KC, N’dri-Yoman AT, et al. Child-Pugh-Turcott versus Meld score for predicting survival in a retrospective cohort of black African cirrhotic patients. World J Gastroenterol 2008; 14: 286-91.
35. Kim MY, Baik SK, Won CS, et al. Dobutamine stress echocardiography and cirrhotic cardiomyopathy. Korean J Hepatol 2010; 16: 376-82.
36. Zardi EM, Abbate A, Zardi DM, et al. Cirrhotic cardiomyopathy. J Coll Cardiol 2010; 56: 539-49.
37. Kim MY, Baik SK. Cirrhotic cardiomyopathy. Korean J Hepatol 2007; 13: 22-6.
38. Wong F, Girgrah N, Graba J, et al. The cardiac response to exercise in cirrhosis. Gut 2001; 49: 268-75.
39. Cazzaniga M, Salerno F, Pagnozzi G, et al. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut 2007; 56: 869-75.
40. Valeriano V, Funaro S, Lionetti R, et al. Modification of cardiac function in cirrhotic patients with and without ascites. J Am J Gastroenterol 2000; 95: 3200-5.
41. Coutu P, Bennett CN, Favre EG, et al. Parvalbumin corrects slowed relaxation in adult cardiac myocytes expressing hypertrophic cardiomyopathy-linked-tropomyosin mutations. Circ Res 2004; 94: 1235-41.
42. Møller S, Henriksen JH. Cardiovascular dysfunction in cirrhosis. Pathophysiological evidence of a cirrhotic cardiomyopathy. Scand J Gastroenterol 2001; 36: 785-94.
43. Finucci G, Desideri A, Sacerdoti D, et al. Left ventricular diastolic function in liver cirrhosis. Scand J Gastroenterol 1996; 31: 279-84.
44. Hendrickse MT, Triger DR. Vagal dysfunction and impaired urinary sodium and water excretion in cirrhosis. Am J Gastroenterol 1994; 89: 750-7.
45. Ward CA, Ma Z, Lee SS, Giles WR. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am J Physiol 1997; 273: 537-44.
46. Genovesi S, Prata Pizzala DM, Pozzi M, et al. QT interval prolongation and decreased heart rate variability in cirrhotic patients: relevance of hepatic venous pressure gradient and serum calcium. Clin Sci (Lond) 2009; 116: 851-9.
47. Henriksen JH, Fuglsang S, Bendtsen F, et al. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol 2002; 36: 513-20.
48. Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol 2006; 44: 994-1002.
49. Bal JS, Thuluvath PJ. Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver Int 2003; 23: 243-8.
50. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316.
51. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006; 92: 843-9.
52. Padillo J, Rioja P, Muñoz-Villanueva MC, et al. BNP as marker of heart dysfunction in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2010; 22: 1331-6.
53. Pimenta J, Paulo C, Gomes A, et al. B-type natriuretic peptide is related to cardiac function and prognosis in hospitalized patients with decompensated cirrhosis. Liver Int 2010; 30: 1059-66.
54. Yilmaz VT, Eken C, Avci AB, et al. Relationship of increased serum brain natriuretic peptide levels with hepatic failure, portal hypertension and treatment in patients with cirrhosis. Turk J Gastroenterol 2010; 21: 381-6.
55. Cavaşi A, Cavaşi E, Grigorescu M, Sitar-Tăut A. Relationship between NT-proBNP and cardio-renal dysfunction in patients with advanced liver cirrhosis. J Gastrointest Liver Dis 2014; 23: 51-6.
56. Radvan M, Svoboda P, Radyanova J, et al. Brain natriuretic peptide in decompensation of liver cirrhosis in non-cardiac patients. Hepatogastroenterology 2009; 56: 181-5.
57. Kim YK, Seong SH, Jun IG, et al. Prooperative echocardiographic indices associated with elevated brain natriuretic peptide in liver transplant recipients. Transplant Proc 2011; 43: 1691-5.

Received: 13.03.2015
Accepted: 8.11.2015